Three Months Ended January 31,

Nine Months Ended January 31,

2018

2017

2018

2017

Revenues:

Chinese medicine - third party

$ 675,927

$ 859,933

$ 2,099,147

$ 2,240,055

Chinese medicine - related party

0

Total Chinese medicine

675,927

859,933

2,099,147

2,240,055

Stevioside - third party

4,058,336

3,421,023

11,135,229

8,413,018

Stevioside - related party

1,591,329

2,129,371

1,858,709

5,591,740

Total Stevioside

5,649,665

5,550,394

12,993,938

14,004,758

Total segment and consolidated revenues

$ 6,325,592

$ 6,410,327

$ 15,093,085

$ 16,244,813

Interest income (expense):

Chinese medicine

$ 386

$ 105

$ 742

$ 178

Stevioside

(152,055)

(100,363)

(387,670)

(270,334)

Total segment and consolidated interest expense

$ (151,669)

$ (100,258)

$ (386,928)

$ (270,156)

Depreciation and amortization:

Chinese medicine

$ 33,531

$ 70,011

$ 170,961

$ 218,060

Stevioside

300,818

356,809

1,032,021

1,057,808

Total segment and consolidated depreciation and amortization

$ 334,349

$ 426,820

$ 1,202,982

$ 1,275,868

Loss before income taxes:

Chinese medicine

$ (6,964)

$ (38,147)

$ (521,873)

$ (188,043

Stevioside

(551,179)

(508,840)

(2,278,166)

(1,336,510

Corporate and other

(314,667)

(358,697)

(1,021,871)

(1,125,711

Total consolidated loss before income taxes

$ (872,810)

$ (905,684)

$ (3,821,910)

$ (2,650,264